Neoadjuvant Therapy of Cervical Carcinoma with the Angiogenesis Inhibitor Bevacizumab: a Single-Centre Analysis
- Alternative title
-
Neoadjuvante Therapie des Zervixkarzinoms mit dem Angiogeneseinhibitor Bevacizumab: eine monozentrische Auswertung
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Neoadjuvant Therapy of Cervical Carcinoma with the Angiogenesis Inhibitor Bevacizumab: a Single-Centre Analysis ; volume:78 ; number:08 ; year:2018 ; pages:768-774
Geburtshilfe und Frauenheilkunde ; 78, Heft 08 (2018), 768-774
- Contributor
-
Junker, Philip
Puppe, Julian
Thangarajah, Fabinshy
Domröse, Christian
Cepic, Angela
Morgenstern, Bernd
Ratiu, Dominik
Hellmich, Martin
Mallmann, Peter
Wirtz, Marina
- DOI
-
10.1055/a-0641-5588
- URN
-
urn:nbn:de:101:1-2019022307145405541420
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Junker, Philip
- Puppe, Julian
- Thangarajah, Fabinshy
- Domröse, Christian
- Cepic, Angela
- Morgenstern, Bernd
- Ratiu, Dominik
- Hellmich, Martin
- Mallmann, Peter
- Wirtz, Marina
Other Objects (12)
Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903)
ADAR1 overexpression is associated with cervical cancer progression and angiogenesis
Decreased angiogenesis as a possible pathomechanism in cervical degenerative myelopathy
Decreased angiogenesis as a possible pathomechanism in cervical degenerative myelopathy
Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival
Co-delivery of Liposomal Ketoconazole and Bevacizumab for Synergistical Inhibition of Angiogenesis Against Endometrial Cancer
Bevacizumab for the treatment of surgically unresectable cervical cord hemangioblastoma: a case report
Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity
An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Genomic profile predicts the efficacy of neoadjuvant chemotherapy for cervical cancer patients
Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903)
ADAR1 overexpression is associated with cervical cancer progression and angiogenesis
Decreased angiogenesis as a possible pathomechanism in cervical degenerative myelopathy
Decreased angiogenesis as a possible pathomechanism in cervical degenerative myelopathy
Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival
Co-delivery of Liposomal Ketoconazole and Bevacizumab for Synergistical Inhibition of Angiogenesis Against Endometrial Cancer
Bevacizumab for the treatment of surgically unresectable cervical cord hemangioblastoma: a case report
Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity
An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Genomic profile predicts the efficacy of neoadjuvant chemotherapy for cervical cancer patients
Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903)
ADAR1 overexpression is associated with cervical cancer progression and angiogenesis
Decreased angiogenesis as a possible pathomechanism in cervical degenerative myelopathy
Decreased angiogenesis as a possible pathomechanism in cervical degenerative myelopathy
Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival
Co-delivery of Liposomal Ketoconazole and Bevacizumab for Synergistical Inhibition of Angiogenesis Against Endometrial Cancer
Bevacizumab for the treatment of surgically unresectable cervical cord hemangioblastoma: a case report
Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity
An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab